Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Long-Term Debt Repayments (2016 - 2019)

BioRestorative Therapies (BRTX) has disclosed Long-Term Debt Repayments for 9 consecutive years, with $1.4 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Long-Term Debt Repayments rose 165.37% year-over-year to $1.4 million, compared with a TTM value of $3.6 million through Dec 2021, changed N/A, and an annual FY2021 reading of $250000.0, changed N/A over the prior year.
  • Long-Term Debt Repayments was $1.4 million for Q4 2019 at BioRestorative Therapies, up from $1.3 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $1.4 million in Q4 2019 and bottomed at $3.0 in Q2 2017.
  • Average Long-Term Debt Repayments over 5 years is $410598.9, with a median of $160864.5 recorded in 2018.
  • The sharpest move saw Long-Term Debt Repayments plummeted 99.98% in 2017, then surged 994633.33% in 2018.
  • Year by year, Long-Term Debt Repayments stood at $5000.0 in 2015, then skyrocketed by 7060.0% to $358000.0 in 2016, then tumbled by 39.62% to $216176.0 in 2017, then soared by 136.72% to $511731.0 in 2018, then surged by 165.37% to $1.4 million in 2019.
  • Business Quant data shows Long-Term Debt Repayments for BRTX at $1.4 million in Q4 2019, $1.3 million in Q3 2019, and $886629.0 in Q2 2019.